This trial will help to improve the reproductive health of women with lupus by testing whether a patient educational tool can help them better understand and adhere to taking aspirin, which has been shown to reduce the risk of preeclampsia.
1 Primary · 3 Secondary · Reporting Duration: Up to and including 12 weeks of pregnancy, at 20 to 24 weeks of pregnancy, at 30 to 34 weeks of pregnancy, and 8 to 12 weeks after delivery
80 Total Participants · 2 Treatment Groups
Primary Treatment: Patient Educational Tool · No Placebo Group · N/A
Age 18 - 45 · Female Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: